Gene
HGF
HGF is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (96), Actionable biomarkers (2), Trial mentions (137), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention HGF. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 21 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 8 of 8,275 | 0.10% | 76 of 11,460 | 0.66% |
| 2022 | 7 of 8,285 | 0.08% | 90 of 13,598 | 0.66% |
| 2021 | 5 of 8,692 | 0.06% | 123 of 15,045 | 0.82% |
| 2020 | 11 of 7,640 | 0.14% | 101 of 14,459 | 0.70% |
| 2019 | 4 of 7,300 | 0.05% | 92 of 12,159 | 0.76% |
| 2018 | 8 of 6,927 | 0.12% | 76 of 11,854 | 0.64% |
| 2017 | 5 of 6,558 | 0.08% | 92 of 11,595 | 0.79% |
Showing 10 of 37 years.
Assay-provider ledger (96)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BIO-RAD Laboratories S.A. (trypan blue) | Reagent supplier | Clinical validationAnalytical validation | 10 | May 28, 2026 +2 undated |
| Nightingale Health | Diagnostic provider | Clinical validation | 1 | May 28, 2026 |
| OLINK Proteomics | Reagent supplier | Clinical validationAnalytical validation | 3 | May 28, 2026 |
| BIO-RAD | Reagent supplier | Clinical validation | 2 | September 26, 2025 |
| Invitrogen by ThermoFisher Scientific | Reagent supplier | Clinical validation | 1 | September 26, 2025 |
Showing 5 of 96 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| HGF amplification + ERBB2 amplification | TRASTUZUMAB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| HGF overexpression | CABOZANTINIB | response-associated | urothelial carcinoma | Cancer Genome Interpreter |
Trial mentions (137)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02802982 | Trial biospecimen (AACT) |
| NCT01596192 | Trial biospecimen (AACT) |
| NCT01233336 | Trial biospecimen (AACT) |
| NCT03175224 | Trial eligibility (AACT) |
| NCT04577703 | Trial eligibility (AACT) |
Showing 5 of 137 trial mentions.
Target-disease associations (735)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal pupillary function | phenotype | GWAS credible sets |
| Abnormality of the pancreas | phenotype | Literature (Europe PMC) |
| Acute hepatic failure | phenotype | Literature (Europe PMC) |
| Acute hepatitis | phenotype | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 735 associations.
Vendor sourcing (379)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AVEO Oncology (United States) | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | are not to be enrolled in the study: * Nasopharyngeal primary site, if WHO Type II or III (non-keratinizing) * History of severe allergic or anaphylactic re... | View trial NCT02277197 |
| AVEO Oncology (United States) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | (hydroxyurea and hypomethylating agents) * Known active HIV, hepatitis B or C or infection. Exception for patients with hepatitis B on antivirals and low vir... | View trial NCT02109627 |
| AVEO Oncology (United States) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Cytologically- or histologically-confirmed pancreatic adenocarcinoma or poorly differentiated pancreatic carcinoma that is metastatic to distant sites. ... | View trial NCT03316599 |
| AVEO Oncology (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | HGF | View trial NCT02109627 |
| AVEO Oncology (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | Hepatocyte growth factor | View trial NCT03316599 |
Showing 5 of 379 sourcing records.
Trial-cited literature (1,225)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Impact of Smoking on the Efficacy of Human Autologous Oral Mucosal Epithelial Cell Sheet Transplantation for Treating Limbal Stem Cell Deficiency. | Stem cells international | 2026 | 0 |
| Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double-Blind, Randomized, Placebo-Controlled Study (LEGenD-1). | Circulation. Cardiovascular interventions | 2026 | 0 |
| Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease. | Ophthalmology and therapy | 2025 | 6 |
| Unraveling Melasma: From Epidermal Pigmentation to Microenvironmental Dysregulation. | Biology | 2025 | 3 |
| Application of allogeneic adult mesenchymal stem cells in the treatment of venous ulcers: A phase I/II randomized controlled trial protocol. | PloS one | 2025 | 3 |
Showing 5 of 1,225 papers.
Protein variant mentions (5)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A432V | 1 | 2016 | PMID 26467025 |
| p.E304K | 1 | 2015 | PMID 25741868 |
| p.K15190D | 1 | 2021 | PMID 34164713 |
| p.N261201100032C | 1 | 2020 | PMID 31992589 |
| p.Q978L | 1 | 2008 | PMID 18709663 |
Literature-extracted relations (163)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Ifosfamide | Chemical | associate |
Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments. | 2023 |
| BEVACIZUMAB | Chemical | associate |
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). | 2022 |
| EVEROLIMUS | Chemical | negative_correlate |
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. | 2021 |
| Crizotinib | Chemical | interact |
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-<i>MET</i> mRNA methylation. | 2020 |
| PROPOFOL | Chemical | negative_correlate |
The influence of dexmedetomidine and propofol on circulating cytokine levels in healthy subjects. | 2019 |
Showing 5 of 163 relation assertions.
Organizations publishing (736)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mass General Brigham | Hospital | 36 | 2007 to 2026 |
| Government of the United States of America | Government | 35 | 2005 to 2025 |
| Harvard Medical School | Academic | 34 | 2000 to 2023 |
| The University of Texas System | Academic | 26 | 2009 to 2023 |
| Dana-Farber Cancer Institute | Other | 23 | 2011 to 2023 |
Showing 5 of 736 organizations.
Where HGF appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
661 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.